Skip to main content

Advertisement

Table 5 Adjusted risk of inappropriate empiric therapy, hospital mortality, excess LOS and costs

From: Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis

  Marginal effect, CSE Marginal effect, CRE Adjusted relative risk ratio/excess days or costs (95% confidence interval) P-value
Risk of IET
 Parse Model 11.8% 47.7% 3.95 (3.51, 4.46) <0.001
 Propensity score (based on 100% CRE cases matched to CSE 1:1) 13.1% 55.8% 4.27 (3.64, 5.00) <0.001
 Non-parse model 11.9% 47.7% 4.00 (3.48, 4.59) <0.001
  Marginal effect, non-IET Marginal effect, IET Adjusted relative risk ratio/excess days or costs (95% confidence interval) P-value
Risk of death
 Hierarchical model 9.8% 11.0% 1.12 (1.03, 1.23) 0.013
 Propensity score (based on 96.4% IET cases matched to non-IET 1:1) 10.5% 11.9% 1.13 (1.01, 1.27) 0.030
Length of stay (days)
 Hierarchical model 8.2 13.4 5.2 (4.8, 5.6) <0.001
 Propensity score (based on 96.4% IET cases matched to non-IET 1:1) 9.6 14.6 5.0 (4.4, 5.6) <0.001
Hospital costs
 Hierarchical model $20,508 $30,819 $10,312 ($9497, $11,126) <0.001
 Propensity score (based on 96.4% IET cases matched to non-IET 1:1) $22,005 $32,837 $10,831 ($9254, $12,409) <0.001
  1. IET inappropriate empiric therapy, CSE carbapenem sensitive Enterobacteriaceae, CRE carbapenem resistant Enterobacteriaceae